Introduction
GSK plc (LSE:GSK) has spent recent years trying to rebuild credibility in oncology after divesting much of its cancer portfolio in the mid-2010s. Jemperli, the brand name for the anti-PD-1 antibody dostarlimab, sits at the centre of that effort. The central question for investors is how much this single franchise can underpin GSK's oncology ambitions.
Jemperli is approved in the UK, EU and US for endometrial cancer, both as a monotherapy for pre-treated mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) disease and, separately, in a first-line combination with platinum chemotherapy that has been broadened to an all-comer population. The US additionally carries a tissue-agnostic dMMR solid-tumour indication under accelerated approval. GSK has reported Jemperli as a named oncology growth driver, while further expansion, notably investigational research in rectal cancer, remains unproven. Commercial performance will depend on competition, reimbursement and clinical data.
What is Jemperli and how does it work?
Jemperli is GSK's brand for dostarlimab (in the US, the approved substance name is dostarlimab-gxly). According to the approved product information, it is a humanised IgG4 monoclonal antibody that blocks programmed cell death protein-1 (PD-1) on T cells.
By binding PD-1 and blocking its interaction with the ligands PD-L1 and PD-L2, dostarlimab releases PD-1 pathway-mediated inhibition of the immune response, including anti-tumour immunity. This places it in the same broad immuno-oncology class as several established checkpoint inhibitors.
The molecule was originally discovered by AnaptysBio and licensed to TESARO. GSK acquired TESARO in January 2019, bringing dostarlimab into its oncology portfolio. Jemperli is a direct GSK product, marketed by GSK group companies, with GlaxoSmithKline (UK) Limited holding the Great Britain marketing authorisation; it is not structured as a ViiV- or Alexion-type joint venture.
Why is Jemperli strategically important to GSK?
For GSK, Jemperli represents more than a single medicine. It is a signal that the company can develop and commercialise a checkpoint inhibitor in a competitive field long dominated by larger immuno-oncology players. The company has positioned Jemperli as a key oncology franchise in its reporting.
The strategic value rests on lifecycle expansion. The original approvals were narrow, but the first-line endometrial cancer combination has since broadened to an all-comer population, materially widening the addressable patient group without requiring an entirely new asset. GSK separately discloses Jemperli turnover as a named growth driver in its financial reporting, though no specific revenue figure, market-share percentage or efficacy percentage is asserted here, as none was verified against a primary GSK financial disclosure in this check.
A live UK marketing authorisation exists, held by GlaxoSmithKline (UK) Limited. It is worth noting that an MHRA or regulatory substance listing only evidences that regulatory product files exist; it is not, by itself, proof of new approval, ownership change, launch or commercial success. Those are separate matters established by the specific approvals and by company disclosure.
What are the current approved uses?
Jemperli's approved indications are concentrated in endometrial cancer, with one additional tissue-agnostic use in the US only. Investors should keep jurisdictions distinct, because labelling differs across the UK, EU and US.
In the UK, per the emc Summary of Product Characteristics last revised 25 February 2026, Jemperli is indicated as monotherapy for adults with dMMR/MSI-H recurrent or advanced endometrial cancer that has progressed on or following prior platinum-containing treatment, and, separately, in combination with platinum-containing chemotherapy for adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. The combination is an all-comer indication, not restricted by biomarker; the monotherapy remains restricted to dMMR/MSI-H.
In the EU, the European Commission first approved monotherapy for dMMR/MSI-H recurrent or advanced endometrial cancer on 21 April 2021, described as the first anti-PD-1 for that setting in Europe. The first-line combination with carboplatin and paclitaxel was expanded to an all-comer population by a decision announced on 20 January 2025. The EU has no tissue-agnostic dMMR solid-tumour indication.
In the US, the FDA granted accelerated approval for dMMR endometrial cancer on 22 April 2021, later converted to regular approval on 10 February 2023. A tissue-agnostic dMMR solid-tumour indication was granted under accelerated approval on 17 August 2021, with continued approval contingent on confirmatory trials. The chemotherapy combination, first approved on 31 July 2023, was expanded to all adult patients on 1 August 2024.
What additional indications are under study?
The most closely watched expansion opportunity is in rectal cancer, and here the important caution is that this use is investigational only. Dostarlimab is not approved anywhere in the world for rectal cancer.
The US FDA granted Breakthrough Therapy Designation for dostarlimab in locally advanced dMMR/MSI-H rectal cancer on 16 December 2024, and the AZUR-1 registrational programme is ongoing. Breakthrough designation can support faster interaction with regulators but does not guarantee approval, and timing is uncertain.
Investors should treat any rectal cancer opportunity as potential rather than established. Regulatory success would depend on confirmatory data and a formal filing and review process. Until then, the addressable market beyond endometrial cancer remains a research thesis, not a commercial reality.
How large is the addressable market?
Endometrial cancer is one of the more common gynaecological cancers in developed markets, and first-line advanced or recurrent disease is a meaningful treatment setting. The move to an all-comer combination indication broadened Jemperli's eligible population beyond the dMMR/MSI-H subgroup that defined its earliest approvals.
Any expansion into rectal cancer, were it to be approved, could extend the addressable population further, but that remains investigational. The US tissue-agnostic dMMR indication also adds breadth in that jurisdiction, subject to confirmatory-trial obligations.
No fabricated market-size figures are offered here. Where GSK does not separately disclose granular product revenue detail, that limitation should be acknowledged rather than filled with estimates. The qualitative picture is of a franchise whose reach has widened through label expansion rather than through a single launch.
How strong is the competitive environment?
The immuno-oncology field in endometrial cancer is competitive, and Jemperli faces established rivals. The most direct competition comes from other checkpoint inhibitors used with chemotherapy in the frontline setting.
Pembrolizumab (Keytruda, from MSD/Merck) is an anti-PD-1 approved with chemotherapy for frontline advanced or recurrent endometrial cancer, with lenvatinib for previously treated disease, and as monotherapy for MSI-H/dMMR tumours, including tissue-agnostic use. Durvalumab (Imfinzi, from AstraZeneca) is an anti-PD-L1 approved with carboplatin and paclitaxel for dMMR primary advanced or recurrent endometrial cancer.
Other immuno-oncology agents, including nivolumab (Opdivo, from Bristol Myers Squibb) and avelumab (Bavencio, from Merck KGaA/Pfizer), compete in the broader landscape. This crowded field means clinical differentiation, guideline positioning and reimbursement decisions could each influence how Jemperli is used relative to alternatives.
What could support future growth?
Several factors could support Jemperli's trajectory. The all-comer expansion of the first-line combination across the UK, EU and US is the most tangible, because it removes the biomarker restriction on the combination and broadens the eligible population.
Lifecycle management is a further driver. GSK's strategy of layering additional indications onto an existing asset can extend commercial life without the cost and risk of a wholly new molecule. The investigational rectal cancer programme, if it were to succeed, is cited by GSK as significant future potential, though it is not approved.
GSK has reported Jemperli as a named oncology growth driver, which suggests continued commercial focus. Data supporting the combination indications, drawn from the RUBY programme, could reinforce prescriber confidence where clinical results suggest benefit. Investors may monitor upcoming trial readouts, regulatory decisions and reimbursement outcomes.
What could limit commercial uptake?
Against those drivers sit clear risks. The US tissue-agnostic dMMR solid-tumour indication was granted under accelerated approval and remains contingent on confirmatory trials; failure to verify clinical benefit could lead to withdrawal or restriction of that indication.
Competitive intensity is a second constraint. Pembrolizumab plus chemotherapy and durvalumab plus chemotherapy are both established options in overlapping settings, and share of the frontline market cannot be assumed. The rectal cancer opportunity is investigational only, and approval is not guaranteed.
Reimbursement is a further hurdle, particularly in the UK, where the National Institute for Health and Care Excellence and the Scottish Medicines Consortium assess cost-effectiveness. NICE has appraised dostarlimab with platinum chemotherapy for endometrial cancer, and access can depend on such decisions. Longer term, general pharmaceutical risks apply: eventual patent expiry and biosimilar competition for a biologic, pricing pressure, jurisdictional divergence in labelling, potential immune-related adverse events, and the manufacturing complexity of a biologic. None of these should be read as advice to act on the shares.
What should investors monitor?
For a general investor audience, a few markers stand out. Progress of the AZUR-1 rectal cancer programme and any regulatory filings would indicate whether the pipeline thesis is maturing, though nothing here is approved.
Confirmatory-trial outcomes for the US tissue-agnostic indication matter for the durability of that accelerated approval. Reimbursement decisions in the UK and other markets will influence real-world access. Competitive dynamics against pembrolizumab and durvalumab in frontline endometrial cancer remain central.
GSK's own disclosures, in quarterly and annual reporting, are the authoritative source for how the franchise is performing commercially. Where the company does not separate out specific figures, investors should rely on that disclosure rather than on estimates. This article does not recommend buying, selling or holding the shares.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...